217 results on '"Tortella FC"'
Search Results
2. Differential Effect of Nicotinamide on Circulating Damage Marker Profiles Following Controlled Cortical Impact, Parasagittal Fluid Percussion, and Penetrating Ballistic-Like Brain Injury: Results from Operation Brain Trauma Therapy
- Author
-
Mondello, Stefania, Kochanek, P. M., Bramlett, H. M., Dixon, Ce, Shear, Da, Schmid, K., Dietrich, Wd, Wang, K. K., Hayes, Rl, Povlishock, Jj, and Tortella, Fc
- Published
- 2012
3. Persistent vegetative state following severe traumatic brain injury (GCS ≤ 8) is associated with brain-reactive antibodies in serum
- Author
-
Mondello, Stefania, Yang, B., Zoltewicz, S., Gabrielli, A., Catani, S., D'Ippolito, M., Seaney, Jm, Schmid, K., Tortella, Fc, Wang, Kk, Hayes, Rl, and Formisano, R.
- Published
- 2012
4. In vivo monitoring of cytokines and brain biomarker damage following severe traumatic brain injury: a microdialysis study
- Author
-
Mondello, Stefania, Jeromin, A., Bullock, R., Mo Sweaney, J., Streeter, J., Schmid, K., Tortella, Fc, Hayes, R., and Wang, K. K.
- Published
- 2011
5. Quantitative cerebrospinal fluid biokinetic parameters of alpha II-spectrin breakdown products in severe traumatic brain injury patients
- Author
-
Brophy, G., Mondello, Stefania, Papa, L., Robicsek, S., Gabrielli, A., Tepas, J., Buki, A., Robertson, C., Tortella, Fc, Wang, K., and Hayes, R.
- Published
- 2011
6. Role of serum biomarkers in individuals in coma or vegetative state after traumatic brain injury
- Author
-
Mondello, Stefania, Gabrielli, A., Catani, S., D'Ippolito, M., Kara, Schmid, Tortella, Fc, Wang, Kk, Hayes, Rl, and Formisano, R.
- Published
- 2011
7. MAP-2 concentration in serum of patients after Traumatic Brain Injury: Insight into the Pathophysiological Mechanisms of the Chronic Phase
- Author
-
Mondello, Stefania, Gabrielli, A., Catani, S., D'Ippolito, M., Schmid, K., Tortella, Fc, Wang, Kk, Hayes, Rl, and Formisano, R.
- Published
- 2011
8. Diffuse Injury and Focal Mass Lesion are associated with Different Biomarker Profiles after severe traumatic brain injury
- Author
-
Mondello, Stefania, Bullock, R., Buki, A., Jeromin, A., Papa, L., Kara, Schmid, Tortella, Fc, Wang, Kk, and Hayes, Rl
- Published
- 2011
9. Development of A TBI Diagnostic Assay System For Multiple Levels Of Care
- Author
-
Schmid, K., Müller, U., Wang, K., Akinyi, L., Scharf, D., Mondello, Stefania, Streeter, J., Hayes, Rl, and Tortella, Fc
- Published
- 2010
10. Changes in Brain Biomarkers and Brain Tissue Oxygenation Following Severe Head Injury: A Case Series
- Author
-
Mondello, Stefania, Papa, L., Buki, A., Bullock, R., Brophy, G., Robertson, Cs, Czeiter, E., Ezer, E., Justin, Blaber, Tortella, Fc, Wang, Kk, and Hayes, Rl
- Published
- 2010
11. Ubiquitin C-Terminal Hydrolase (UCH-L1): Correlations Exist Between Biofluid Kinetics and Clinical Outcome In Severe Traumatic Brain Injury Patients
- Author
-
Brophy, G., Mondello, Stefania, Papa, L., Robicsek, S., Gabrielli, A., Tepas, J., Buki, A., Robertson, C., Tortella, Fc, Wang, K., and Hayes, R.
- Published
- 2010
12. Toward Improved Prediction of Outcome In Traumatic Brain Injury: Comparison Between Computed Tomographic Classifications And The Serum Biomarker UCH-L1
- Author
-
Mondello, Stefania, Papa, L., Bullock, R., Buki, A., Brophy, G., Robertson, Cs, Czeiter, E., Tortella, Fc, Wang, Kk, and Hayes, Rl
- Published
- 2010
13. Brain biomarkers and brain tissue oxygenation: changes and correlations following severe head injury
- Author
-
Mondello, S, primary, Buki, A, additional, Bullock, R, additional, Robertson, CS, additional, Czeiter, E, additional, Ezer, E, additional, Tortella, FC, additional, Wang, KK, additional, and Hayes, RL, additional
- Published
- 2010
- Full Text
- View/download PDF
14. Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention.
- Author
-
Papa L, Lewis LM, Silvestri S, Falk JL, Giordano P, Brophy GM, Demery JA, Liu MC, Mo J, Akinyi L, Mondello S, Schmid K, Robertson CS, Tortella FC, Hayes RL, Wang KK, Papa, Linda, Lewis, Lawrence M, Silvestri, Salvatore, and Falk, Jay L
- Published
- 2012
- Full Text
- View/download PDF
15. Seizures and Cognitive Outcome After Traumatic Brain Injury: A Post Hoc Analysis.
- Author
-
Foreman B, Lee H, Mizrahi MA, Hartings JA, Ngwenya LB, Privitera M, Tortella FC, Zhang N, and Kramer JH
- Subjects
- Adult, Cognition, Humans, Male, Middle Aged, Prospective Studies, Seizures diagnosis, Young Adult, Brain Injuries, Traumatic complications, Electroencephalography methods
- Abstract
Introduction: Seizures and abnormal periodic or rhythmic patterns are observed on continuous electroencephalography monitoring (cEEG) in up to half of patients hospitalized with moderate to severe traumatic brain injury (TBI). We aimed to determine the impact of seizures and abnormal periodic or rhythmic patterns on cognitive outcome 3 months following moderate to severe TBI., Methods: This was a post hoc analysis of the multicenter randomized controlled phase 2 INTREPID
2566 clinical trial conducted from 2010 to 2016 across 20 United States Level I trauma centers. Patients with nonpenetrating TBI and postresuscitation Glasgow Coma Scale scores 4-12 were included. Bedside cEEG was initiated per protocol on admission to intensive care, and the burden of ictal-interictal continuum (IIC) patterns, including seizures, was quantified. A summary global cognition score at 3 months following injury was used as the primary outcome., Results: 142 patients (age mean + / - standard deviation 32 + / - 13 years; 131 [92%] men) survived with a mean global cognition score of 81 + / - 15; nearly one third were considered to have poor functional outcome. 89 of 142 (63%) patients underwent cEEG, of whom 13 of 89 (15%) had severe IIC patterns. The quantitative burden of IIC patterns correlated inversely with the global cognition score (r = - 0.57; p = 0.04). In multiple variable analysis, the log-transformed burden of severe IIC patterns was independently associated with the global cognition score after controlling for demographics, premorbid estimated intelligence, injury severity, sedatives, and antiepileptic drugs (odds ratio 0.73, 95% confidence interval 0.60-0.88; p = 0.002)., Conclusions: The burden of seizures and abnormal periodic or rhythmic patterns was independently associated with worse cognition at 3 months following TBI. Their impact on longer-term cognitive endpoints and the potential benefits of seizure detection and treatment in this population warrant prospective study., (© 2021. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.)- Published
- 2022
- Full Text
- View/download PDF
16. N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats.
- Author
-
Witkin JM, Cerne R, Newman AH, Izenwasser S, Smith JL, and Tortella FC
- Subjects
- Alcohols chemistry, Animals, Anticonvulsants metabolism, Binding Sites, Dextromethorphan metabolism, Dextrorphan metabolism, Disease Models, Animal, Excitatory Amino Acid Antagonists metabolism, Infusions, Intraventricular, Ligands, Male, Rats, Rats, Sprague-Dawley, Receptors, N-Methyl-D-Aspartate metabolism, Receptors, sigma metabolism, Treatment Outcome, Sigma-1 Receptor, Anticonvulsants administration & dosage, Dextromethorphan administration & dosage, Dextromethorphan analogs & derivatives, Dextrorphan administration & dosage, Excitatory Amino Acid Agonists adverse effects, Excitatory Amino Acid Antagonists administration & dosage, N-Methylaspartate adverse effects, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Seizures chemically induced, Seizures drug therapy
- Abstract
Interest in developing NMDA receptor antagonists with reduced side-effects for neurological and psychiatric disorders has been re-energized by the recent introduction of esketamine into clinical practice for treatment-resistant depression. Structural analogs of dextromethorphan bind with low affinity to the NMDA receptor ion channel, have functional effects in vivo, and generally display a lower propensity for side-effects than that of ketamine and other higher affinity antagonists. As such, the aim of the present study was to determine whether a series of N-substituted-3-alkoxy-substituted dextromethorphan analogs produce their anticonvulsant effects through NMDA receptor blockade. Compounds were studied against NMDA-induced seizures in rats. Compounds were administered intracerebroventricularly in order to mitigate confounds of drug metabolism that arise from systemic administration. Comparison of the anticonvulsant potencies to their affinities for NMDA, σ1, and σ2 binding sites were made in order to evaluate the contribution of these receptors to anticonvulsant efficacy. The potencies to block convulsions were positively associated with their affinities to bind to the NMDA receptor ion channel ([
3 H]-TCP binding) (r = 0.71, p < 0.05) but not to σ1 receptors ([3 H]-SKF 10047 binding) (r = -0.31, p = 0.46) or to σ2 receptors ([3 H]-DTG binding) (p = -0.38, p = 0.36). This is the first report demonstrating that these dextromethorphan analogs are functional NMDA receptor antagonists in vivo. Given their potential therapeutic utility and favorable side-effect profiles, such low affinity NMDA receptor antagonists could be considered for further development in neurological (e.g., anticonvulsant) and psychiatric (e.g., antidepressant) disorders., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
17. Continuous Electroencephalography After Moderate to Severe Traumatic Brain Injury.
- Author
-
Lee H, Mizrahi MA, Hartings JA, Sharma S, Pahren L, Ngwenya LB, Moseley BD, Privitera M, Tortella FC, and Foreman B
- Subjects
- Adult, Cohort Studies, Female, Glasgow Outcome Scale, Humans, Intensive Care Units, Male, Middle Aged, Prognosis, Prospective Studies, Treatment Outcome, Brain Injuries, Traumatic physiopathology, Brain Injuries, Traumatic rehabilitation, Critical Illness therapy, Electroencephalography methods, Severity of Illness Index
- Abstract
Objectives: After traumatic brain injury, continuous electroencephalography is widely used to detect electrographic seizures. With the development of standardized continuous electroencephalography terminology, we aimed to describe the prevalence and burden of ictal-interictal patterns, including electrographic seizures after moderate-to-severe traumatic brain injury and to correlate continuous electroencephalography features with functional outcome., Design: Post hoc analysis of the prospective, randomized controlled phase 2 multicenter INTREPID study (ClinicalTrials.gov: NCT00805818). Continuous electroencephalography was initiated upon admission to the ICU. The primary outcome was the 3-month Glasgow Outcome Scale-Extended. Consensus electroencephalography reviews were performed by raters certified in standardized continuous electroencephalography terminology blinded to clinical data. Rhythmic, periodic, or ictal patterns were referred to as "ictal-interictal continuum"; severe ictal-interictal continuum was defined as greater than or equal to 1.5 Hz lateralized rhythmic delta activity or generalized periodic discharges and any lateralized periodic discharges or electrographic seizures., Setting: Twenty U.S. level I trauma centers., Patients: Patients with nonpenetrating traumatic brain injury and postresuscitation Glasgow Coma Scale score of 4-12 were included., Interventions: None., Measurements and Main Results: Among 152 patients with continuous electroencephalography (age 34 ± 14 yr; 88% male), 22 (14%) had severe ictal-interictal continuum including electrographic seizures in four (2.6%). Severe ictal-interictal continuum burden correlated with initial prognostic scores, including the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (r = 0.51; p = 0.01) and Injury Severity Score (r = 0.49; p = 0.01), but not with functional outcome. After controlling clinical covariates, unfavorable outcome was independently associated with absence of posterior dominant rhythm (common odds ratio, 3.38; 95% CI, 1.30-9.09), absence of N2 sleep transients (3.69; 1.69-8.20), predominant delta activity (2.82; 1.32-6.10), and discontinuous background (5.33; 2.28-12.96) within the first 72 hours of monitoring., Conclusions: Severe ictal-interictal continuum patterns, including electrographic seizures, were associated with clinical markers of injury severity but not functional outcome in this prospective cohort of patients with moderate-to-severe traumatic brain injury. Importantly, continuous electroencephalography background features were independently associated with functional outcome and improved the area under the curve of existing, validated predictive models.
- Published
- 2019
- Full Text
- View/download PDF
18. Serum-Based Phospho-Neurofilament-Heavy Protein as Theranostic Biomarker in Three Models of Traumatic Brain Injury: An Operation Brain Trauma Therapy Study.
- Author
-
Yang Z, Zhu T, Mondello S, Akel M, Wong AT, Kothari IM, Lin F, Shear DA, Gilsdorf JS, Leung LY, Bramlett HM, Dixon CE, Dietrich WD, Hayes RL, Povlishock JT, Tortella FC, Kochanek PM, and Wang KKW
- Subjects
- Animals, Biomarkers cerebrospinal fluid, Brain Injuries, Traumatic cerebrospinal fluid, Disease Models, Animal, Levetiracetam pharmacology, Neurofilament Proteins cerebrospinal fluid, Niacinamide pharmacology, Nootropic Agents pharmacology, Rats, Rats, Sprague-Dawley, Theranostic Nanomedicine methods, Vitamin B Complex pharmacology, Biomarkers blood, Brain Injuries, Traumatic blood, Neurofilament Proteins blood
- Abstract
Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase (UCH-L1), markers of glial and neuronal cell body injury, respectively, have been previously selected by the Operation Brain Trauma Therapy (OBTT) pre-clinical therapy and biomarker screening consortium as drug development tools. However, traumatic axonal injury (TAI) also represents a major consequence and determinant of adverse outcomes after traumatic brain injury (TBI). Thus, biomarkers capable of assessing TAI are much needed. Neurofilaments (NFs) are found exclusively in axons. Here, we evaluated phospho-neurofilament-H (pNF-H) protein as a possible new TAI marker in serum and cerebrospinal fluid (CSF) across three rat TBI models in studies carried out by the OBTT consortium, namely, controlled cortical impact (CCI), parasagittal fluid percussion (FPI), and penetrating ballistics-like brain injury (PBBI). We indeed found that CSF and serum pNF-H levels are robustly elevated by 24 h post-injury in all three models. Further, in previous studies by OBTT, levetiracetam showed the most promising benefits, whereas nicotinamide showed limited benefit only at high dose (500 mg/kg). Thus, serum samples from the same repository collected by OBTT were evaluated. Treatment with 54 mg/kg intravenously of levetiracetam in the CCI model and 170 mg/kg in the PBBI model significantly attenuated pNF-H levels at 24 h post-injury as compared to respective vehicle groups. In contrast, nicotinamide (50 or 500 mg/kg) showed no reduction of pNF-H levels in CCI or PBBI models. Our current study suggests that pNF-H is a useful theranostic blood-based biomarker for TAI across different rodent TBI models. In addition, our data support levetiracetam as the most promising TBI drug candidate screened by OBTT to date.
- Published
- 2019
- Full Text
- View/download PDF
19. Operation Brain Trauma Therapy: 2016 Update.
- Author
-
Kochanek PM, Bramlett HM, Dixon CE, Dietrich WD, Mondello S, Wang KKW, Hayes RL, Lafrenaye A, Povlishock JT, Tortella FC, Poloyac SM, Empey P, and Shear DA
- Subjects
- Animals, Biomarkers blood, Cognition drug effects, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay methods, Glial Fibrillary Acidic Protein analysis, Glial Fibrillary Acidic Protein blood, Mass Screening trends, Rats, Rats, Sprague-Dawley injuries, Recovery of Function drug effects, Ubiquitin Thiolesterase analysis, Ubiquitin Thiolesterase blood, Brain Injuries, Traumatic drug therapy, Mass Screening methods
- Abstract
Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.
- Published
- 2018
- Full Text
- View/download PDF
20. Functional and Molecular Correlates after Single and Repeated Rat Closed-Head Concussion: Indices of Vulnerability after Brain Injury.
- Author
-
Mountney A, Boutté AM, Cartagena CM, Flerlage WF, Johnson WD, Rho C, Lu XC, Yarnell A, Marcsisin S, Sousa J, Vuong C, Zottig V, Leung LY, Deng-Bryant Y, Gilsdorf J, Tortella FC, and Shear DA
- Subjects
- Animals, Male, Rats, Rats, Sprague-Dawley, Brain Concussion complications, Brain Concussion pathology, Brain Concussion physiopathology, Disease Models, Animal
- Abstract
Closed-head concussive injury is one of the most common causes of traumatic brain injury (TBI). Isolated concussions frequently produce acute neurological impairments, and individuals typically recover spontaneously within a short time frame. In contrast, brain injuries resulting from multiple concussions can result in cumulative damage and elevated risk of developing chronic brain pathologies. Increased attention has focused on identification of diagnostic markers that can prognostically serve as indices of brain health after injury, revealing the temporal profile of vulnerability to a second insult. Such markers may demarcate adequate recovery periods before concussed patients can return to required activities. We developed a noninvasive closed-head impact model that captures the hallmark symptoms of concussion in the absence of gross tissue damage. Animals were subjected to single or repeated concussive impact and examined using a battery of neurological, vestibular, sensorimotor, and molecular metrics. A single concussion induced transient, but marked, acute neurological impairment, gait alterations, neuronal death, and increased glial fibrillary acidic protein (GFAP) expression in brain tissue. As expected, repeated concussions exacerbated sensorimotor dysfunction, prolonged gait abnormalities, induced neuroinflammation, and upregulated GFAP and tau. These animals also exhibited chronic functional neurological impairments with sustained astrogliosis and white matter thinning. Acute changes in molecular signatures correlated with behavioral impairments, whereas increased times to regaining consciousness and balance impairments were associated with higher GFAP and neuroinflammation. Overall, behavioral consequences of either single or repeated concussive impact injuries appeared to resolve more quickly than the underlying molecular, metabolic, and neuropathological abnormalities. This observation, which is supported by similar studies in other mTBI models, underscores the critical need to develop more objective prognostic measures for guiding return-to-play decisions.
- Published
- 2017
- Full Text
- View/download PDF
21. Acute and subacute microRNA dysregulation is associated with cytokine responses in the rodent model of penetrating ballistic-like brain injury.
- Author
-
Johnson D, Cartagena CM, Tortella FC, Dave JR, Schmid KE, and Boutté AM
- Subjects
- Animals, Biomarkers metabolism, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Male, Military Medicine, Polymerase Chain Reaction, Rats, Rats, Sprague-Dawley, Cytokines metabolism, Head Injuries, Penetrating metabolism, MicroRNAs metabolism
- Abstract
Background: MicroRNAs (miRNAs) are small stable RNAs that regulate translational degradation or repression of genes involved in brain trauma-mediated inflammation. More recently, miRNAs have emerged as potential novel TBI biomarkers. The aim of this study was to determine if a select set of miRNAs (miR-21, Let-7i, miR-124a, miR-146a, miR-107) that were previously associated with TBI models and clinical studies would be dysregulated and correlated to inflammatory cytokine abundance in the rat penetrating ballistic-like brain injury (PBBI) model., Methods: Adult male Sprague-Dawley rats received a unilateral frontal 10% PBBI, which produces a temporary cavity. Sham animals received a craniotomy only. Ipsilateral brain tissue and serum were collected 4 hours to 7 days post-injury. Quantitation of miR-21, Let-7i, miR-124a, miR-146a, or miR-107 levels was conducted using Taqman PCR assays normalized to the endogenous reference, U6 snRNA. Brain tissue derived from matching cohorts was used to determine 1L-1beta and IL-6 levels by enzyme-linked immunosorbent assay., Results: Brain tissue Let-7i and miR-21 increased at 4 hours and 1 day, whereas miR-124a and miR-107 were enhanced only 1 day post-injury. MiR-146a displayed a biphasic response and increased 1 day and 7 days, whereas elevation of miR-21 was sustained 1 day to 7 days after PBBI. Pathway analysis indicated that miRNAs were linked to inflammatory proteins, IL-6 and IL-1beta. Confirmation by enzyme-linked immunosorbent assay indicated that both cytokines were increased and peaked at 1 day, but fell at 3 days through 7 days after PBBI, indicating an inverse relationship with miRNA abundance. Serum Let-7i, alone, was differentially abundant 7 days after PBBI., Conclusion: Brain tissue-derived miRNAs linked to increased cytokine levels demonstrates a plausible therapeutic target of TBI-induced inflammation. Suppression of serum derived Let-7i may have utility as a biomarker of subacute injury progression or therapeutic responses.
- Published
- 2017
- Full Text
- View/download PDF
22. Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury.
- Author
-
Lu XM, Cao Y, Mountney A, Liao Z, Shear DA, and Tortella FC
- Subjects
- Animals, Dose-Response Relationship, Drug, Drug Therapy, Combination, Electroencephalography, Gabapentin, Levetiracetam, Male, Piracetam pharmacology, Rats, Rats, Sprague-Dawley, Amines pharmacology, Cyclohexanecarboxylic Acids pharmacology, Head Injuries, Penetrating complications, Piracetam analogs & derivatives, Seizures drug therapy, Seizures etiology, gamma-Aminobutyric Acid pharmacology
- Abstract
Background: Posttraumatic seizures are a medical problem affecting patients with traumatic brain injury. Yet effective treatment is lacking owing to the limitations of antiepileptic drugs (AEDs) applicable to these patients., Methods: In this study, we evaluated the dose-response efficacy of levetiracetam (12.5-100.0 mg/kg) and gabapentin (1.25-25.0 mg/kg) administered either individually or in pairs at fixed-dose ratios as a combination in mitigating posttraumatic nonconvulsive seizures induced by severe penetrating ballistic-like brain injury (PBBI) in rats. Seizures were detected by continuous electroencephalogram (EEG) monitoring for 72 hours postinjury. Animals were treated twice per day for 3 days by intravenous injections., Results: Both levetiracetam (25-100 mg/kg) and gabapentin (6.25-25 mg/kg) significantly reduced PBBI-induced seizure frequency by 44% to 73% and 61% to 69%, and seizure duration by 45% to 64% and 70% to 78%, respectively. However, the two drugs manifested different dose-response profiles. Levetiracetam attenuated seizure activity in a dose-dependent fashion, whereas the beneficial effects of gabapentin plateaued across the three highest doses tested. Combined administration of levetiracetam and gabapentin mirrored the more classic dose-response profile of levetiracetam monotherapy. However, no additional benefit was derived from the addition of gabapentin. Furthermore, isobolographic analysis of the combination dose-response profile of levetiracetam and gabapentin failed to reach the expected level of additivity, suggesting an unlikelihood of favorable interactions between these two drugs against spontaneously occurring posttraumatic seizure activities at the particular set of dose ratios tested., Conclusion: This study was the first attempt to apply isobolographic approach to studying AED combination therapy in the context of spontaneously occurring posttraumatic seizures. Despite the failure to achieve additivity from levetiracetam and gabapentin combination, it is important to recognize the objectivity of the isobolographic approach in the evaluation of AED combination therapy against seizures directly associated with brain injuries.
- Published
- 2017
- Full Text
- View/download PDF
23. Amelioration of Penetrating Ballistic-Like Brain Injury Induced Cognitive Deficits after Neuronal Differentiation of Transplanted Human Neural Stem Cells.
- Author
-
Spurlock MS, Ahmed AI, Rivera KN, Yokobori S, Lee SW, Sam PN, Shear DA, Hefferan MP, Hazel TG, Johe KK, Gajavelli S, Tortella FC, and Bullock RM
- Subjects
- Animals, Brain Injuries, Traumatic diagnosis, Brain Injuries, Traumatic therapy, Cognition Disorders diagnosis, Head Injuries, Penetrating diagnosis, Humans, Random Allocation, Rats, Rats, Inbred F344, Rats, Nude, Rats, Sprague-Dawley, Cell Differentiation physiology, Cognition Disorders therapy, Head Injuries, Penetrating therapy, Neural Stem Cells transplantation, Neurons physiology, Stem Cell Transplantation methods
- Abstract
Penetrating traumatic brain injury (PTBI) is one of the major cause of death and disability worldwide. Previous studies with penetrating ballistic-like brain injury (PBBI), a PTBI rat model revealed widespread perilesional neurodegeneration, similar to that seen in humans following gunshot wound to the head, which is unmitigated by any available therapies to date. Therefore, we evaluated human neural stem cell (hNSC) engraftment to putatively exploit the potential of cell therapy that has been seen in other central nervous system injury models. Toward this objective, green fluorescent protein (GFP) labeled hNSC (400,000 per animal) were transplanted in immunosuppressed Sprague-Dawley (SD), Fisher, and athymic (ATN) PBBI rats 1 week after injury. Tacrolimus (3 mg/kg 2 days prior to transplantation, then 1 mg/kg/day), methylprednisolone (10 mg/kg on the day of transplant, 1 mg/kg/week thereafter), and mycophenolate mofetil (30 mg/kg/day) for 7 days following transplantation were used to confer immunosuppression. Engraftment in SD and ATN was comparable at 8 weeks post-transplantation. Evaluation of hNSC differentiation and distribution revealed increased neuronal differentiation of transplanted cells with time. At 16 weeks post-transplantation, neither cell proliferation nor glial lineage markers were detected. Transplanted cell morphology was similar to that of neighboring host neurons, and there was relatively little migration of cells from the peritransplant site. By 16 weeks, GFP-positive processes extended both rostrocaudally and bilaterally into parenchyma, spreading along host white matter tracts, traversing the internal capsule, and extending ∼13 mm caudally from transplantation site reaching into the brainstem. In a Morris water maze test at 8 weeks post-transplantation, animals with transplants had shorter latency to platform than vehicle-treated animals. However, weak injury-induced cognitive deficits in the control group at the delayed time point confounded benefits of durable engraftment and neuronal differentiation. Therefore, these results justify further studies to progress towards clinical translation of hNSC therapy for PTBI.
- Published
- 2017
- Full Text
- View/download PDF
24. Preclinical modelling of militarily relevant traumatic brain injuries: Challenges and recommendations for future directions.
- Author
-
Cernak I, Stein DG, Elder GA, Ahlers S, Curley K, DePalma RG, Duda J, Ikonomovic M, Iverson GL, Kobeissy F, Koliatsos VE, Leggieri MJ Jr, Pacifico AM, Smith DH, Swanson R, Thompson FJ, and Tortella FC
- Subjects
- Animals, Blast Injuries psychology, Blast Injuries therapy, Brain Injuries, Traumatic psychology, Brain Injuries, Traumatic therapy, Forecasting, Humans, United States epidemiology, Blast Injuries epidemiology, Brain Injuries, Traumatic epidemiology, Disease Models, Animal, Military Personnel psychology, United States Department of Veterans Affairs trends
- Abstract
As a follow-up to the 2008 state-of-the-art (SOTA) conference on traumatic brain injuries (TBIs), the 2015 event organized by the United States Department of Veterans Affairs (VA) Office of Research and Development (ORD) analysed the knowledge gained over the last 7 years as it relates to basic scientific methods, experimental findings, diagnosis, therapy, and rehabilitation of TBIs and blast-induced neurotraumas (BINTs). The current article summarizes the discussions and recommendations of the scientific panel attending the Preclinical Modeling and Therapeutic Development Workshop of the conference, with special emphasis on factors slowing research progress and recommendations for ways of addressing the most significant pitfalls.
- Published
- 2017
- Full Text
- View/download PDF
25. Intravenous Administration of Simvastatin Improves Cognitive Outcome following Severe Traumatic Brain Injury in Rats.
- Author
-
Mountney A, Boutté AM, Gilsdorf J, Lu XC, Tortella FC, and Shear DA
- Subjects
- Administration, Intravenous, Animals, Biomarkers, Disease Models, Animal, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Male, Rats, Rats, Sprague-Dawley, Simvastatin administration & dosage, Behavior, Animal drug effects, Brain Injuries, Traumatic complications, Cognitive Dysfunction drug therapy, Cognitive Dysfunction etiology, Cognitive Dysfunction physiopathology, Head Injuries, Penetrating complications, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Simvastatin pharmacology
- Abstract
Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor commonly used to reduce serum cholesterol. The beneficial effects of oral simvastatin have been reported in pre-clinical models of traumatic brain injury (TBI). The current study was designed to evaluate the potential beneficial effects of simvastatin in a model of severe penetrating TBI using an intravenous (IV) route of administration. Rats were subjected to unilateral frontal penetrating ballistic-like brain injury (PBBI), and simvastatin was delivered intravenously at 30 min and 6 h post-injury and continued once daily for either 4 or 10 days post-PBBI. Motor function was assessed on the rotarod and cognitive performance was evaluated using the Morris water maze (MWM) task. Serum levels of inflammatory cytokines and the astrocytic biomarker, glial fibrillary acidic protein (GFAP), were quantified at 1 h, 4 h, and 24 h post-injury. Histopathological damage was assessed at the terminal end-point. Rotarod testing revealed significant motor deficits in all injury groups but no significant simvastatin-induced therapeutic benefits. All PBBI-injured animals showed cognitive impairment on the MWM test; however, 10-day simvastatin treatment mitigated these effects. Animals showed significantly improved latency to platform and retention scores, whereas the 4-day treatment regimen failed to produce any significant improvements. Biomarker and cytokine analysis showed that IV simvastatin significantly reduced GFAP, interleukin (IL)-1α, and IL-17 serum levels by 4.0-, 2.6-, and 7.0-fold, respectively, at 4 h post-injury. Collectively, our results demonstrate that IV simvastatin provides significant protection against injury-induced cognitive dysfunction and reduces TBI-specific biomarker levels. Further research is warranted to identify the optimal dose and therapeutic window for IV delivery of simvastatin in models of severe TBI.
- Published
- 2016
- Full Text
- View/download PDF
26. Subacute Changes in Cleavage Processing of Amyloid Precursor Protein and Tau following Penetrating Traumatic Brain Injury.
- Author
-
Cartagena CM, Mountney A, Hwang H, Swiercz A, Rammelkamp Z, Boutte AM, Shear DA, Tortella FC, and Schmid KE
- Subjects
- Amyloid beta-Protein Precursor analysis, Animals, Brain metabolism, Brain Injuries, Traumatic pathology, Head Injuries, Penetrating pathology, Male, Rats, Sprague-Dawley, tau Proteins analysis, Amyloid beta-Protein Precursor metabolism, Brain pathology, Brain Injuries, Traumatic metabolism, Head Injuries, Penetrating metabolism, tau Proteins metabolism
- Abstract
Traumatic brain injury (TBI) is an established risk factor for the development of Alzheimer's disease (AD). Here the effects of severe penetrating TBI on APP and tau cleavage processing were investigated in a rodent model of penetrating ballistic-like brain injury (PBBI). PBBI was induced by stereotactically inserting a perforated steel probe through the right frontal cortex of the anesthetized rat and rapidly inflating/deflating the probe's elastic tubing into an elliptical shaped balloon to 10% of total rat brain volume causing temporary cavitation injury. Separate animals underwent probe injury (PrI) alone without balloon inflation. Shams underwent craniectomy. Brain tissue was collected acutely (4h, 24h, 3d) and subacutely (7d) post-injury and analyzed by immunoblot for full length APP (APP-FL) and APP beta c-terminal fragments (βCTFs), full length tau (tau-FL) and tau truncation fragments and at 7d for cytotoxic Beta amyloid (Aβ) peptides Aβ40 and Aβ42 analysis. APP-FL was significantly decreased at 3d and 7d following PBBI whereas APP βCTFs were significantly elevated by 4h post-injury and remained elevated through 7d post-injury. Effects on βCTFs were mirrored with PrI, albeit to a lesser extent. Aβ40 and Aβ42 were significantly elevated at 7d following PBBI and PrI. Tau-FL decreased substantially 3d and 7d post-PBBI and PrI. Importantly, a 22 kDa tau fragment (tau22), similar to that found in AD, was significantly elevated by 4h and remained elevated through 7d post-injury. Thus both APP and tau cleavage was dramatically altered in the acute and subacute periods post-injury. As cleavage of these proteins has also been implicated in AD, TBI pathology shown here may set the stage for the later development of AD or other tauopathies.
- Published
- 2016
- Full Text
- View/download PDF
27. Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy.
- Author
-
Kochanek PM, Bramlett HM, Dixon CE, Shear DA, Dietrich WD, Schmid KE, Mondello S, Wang KK, Hayes RL, Povlishock JT, and Tortella FC
- Subjects
- Animals, Biomarkers, Disease Models, Animal, Humans, Brain Injuries, Traumatic drug therapy, Drug Evaluation, Preclinical
- Abstract
Traumatic brain injury (TBI) was the signature injury in both the Iraq and Afghan wars and the magnitude of its importance in the civilian setting is finally being recognized. Given the scope of the problem, new therapies are needed across the continuum of care. Few therapies have been shown to be successful. In severe TBI, current guidelines-based acute therapies are focused on the reduction of intracranial hypertension and optimization of cerebral perfusion. One factor considered important to the failure of drug development and translation in TBI relates to the recognition that TBI is extremely heterogeneous and presents with multiple phenotypes even within the category of severe injury. To address this possibility and attempt to bring the most promising therapies to clinical trials, we developed Operation Brain Trauma Therapy (OBTT), a multicenter, pre-clinical drug screening consortium for acute therapies in severe TBI. OBTT was developed to include a spectrum of established TBI models at experienced centers and assess the effect of promising therapies on both conventional outcomes and serum biomarker levels. In this review, we outline the approach to TBI modeling, evaluation of therapies, drug selection, and biomarker assessments for OBTT, and provide a framework for reports in this issue on the first five therapies evaluated by the consortium.
- Published
- 2016
- Full Text
- View/download PDF
28. Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
- Author
-
Bramlett HM, Dietrich WD, Dixon CE, Shear DA, Schmid KE, Mondello S, Wang KK, Hayes RL, Povlishock JT, Tortella FC, and Kochanek PM
- Subjects
- Animals, Disease Models, Animal, Glial Fibrillary Acidic Protein blood, Male, Rats, Rats, Sprague-Dawley, Ubiquitin Thiolesterase blood, Biomarkers blood, Brain Injuries, Traumatic, Erythropoietin pharmacology, Neuroprotective Agents pharmacology, Recovery of Function drug effects
- Abstract
Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.
- Published
- 2016
- Full Text
- View/download PDF
29. Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
- Author
-
Dixon CE, Bramlett HM, Dietrich WD, Shear DA, Yan HQ, Deng-Bryant Y, Mondello S, Wang KK, Hayes RL, Empey PE, Povlishock JT, Tortella FC, and Kochanek PM
- Subjects
- Animals, Biomarkers blood, Disease Models, Animal, Glial Fibrillary Acidic Protein blood, Male, Random Allocation, Rats, Rats, Sprague-Dawley, Ubiquitin Thiolesterase blood, Brain Injuries, Traumatic, Cyclosporine pharmacology, Immunosuppressive Agents pharmacology, Recovery of Function drug effects
- Abstract
Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.
- Published
- 2016
- Full Text
- View/download PDF
30. Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy.
- Author
-
Kochanek PM, Bramlett HM, Shear DA, Dixon CE, Mondello S, Dietrich WD, Hayes RL, Wang KK, Poloyac SM, Empey PE, Povlishock JT, Mountney A, Browning M, Deng-Bryant Y, Yan HQ, Jackson TC, Catania M, Glushakova O, Richieri SP, and Tortella FC
- Subjects
- Animals, Disease Models, Animal, Drug Evaluation, Preclinical methods, Male, Neurology methods, Neurology trends, Rats, Rats, Sprague-Dawley, Brain Injuries, Traumatic drug therapy, Drug Evaluation, Preclinical trends, Neuroprotective Agents therapeutic use
- Abstract
Operation Brain Trauma Therapy (OBTT) is a fully operational, rigorous, and productive multicenter, pre-clinical drug and circulating biomarker screening consortium for the field of traumatic brain injury (TBI). In this article, we synthesize the findings from the first five therapies tested by OBTT and discuss both the current work that is ongoing and potential future directions. Based on the results generated from the first five therapies tested within the exacting approach used by OBTT, four (nicotinamide, erythropoietin, cyclosporine A, and simvastatin) performed below or well below what was expected based on the published literature. OBTT has identified, however, the early post-TBI administration of levetiracetam as a promising agent and has advanced it to a gyrencephalic large animal model--fluid percussion injury in micropigs. The sixth and seventh therapies have just completed testing (glibenclamide and Kollidon VA 64), and an eighth drug (AER 271) is in testing. Incorporation of circulating brain injury biomarker assessments into these pre-clinical studies suggests considerable potential for diagnostic and theranostic utility of glial fibrillary acidic protein in pre-clinical studies. Given the failures in clinical translation of therapies in TBI, rigorous multicenter, pre-clinical approaches to therapeutic screening such as OBTT may be important for the ultimate translation of therapies to the human condition.
- Published
- 2016
- Full Text
- View/download PDF
31. Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
- Author
-
Mountney A, Bramlett HM, Dixon CE, Mondello S, Dietrich WD, Wang KK, Caudle K, Empey PE, Poloyac SM, Hayes RL, Povlishock JT, Tortella FC, Kochanek PM, and Shear DA
- Subjects
- Animals, Biomarkers blood, Disease Models, Animal, Glial Fibrillary Acidic Protein blood, Male, Rats, Rats, Sprague-Dawley, Ubiquitin Thiolesterase blood, Brain Injuries, Traumatic, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Neuroprotective Agents pharmacology, Recovery of Function drug effects, Simvastatin pharmacology
- Abstract
Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor used clinically to reduce serum cholesterol. In addition, simvastatin has demonstrated potent antineuroinflammatory and brain edema reducing effects and has shown promise in promoting functional recovery in pre-clinical models of traumatic brain injury (TBI). The purpose of this study was to assess the potential neuroprotective effects of oral administration of simvastatin on neurobehavioral, biomarker, and histopathological outcome measures compared across three pre-clinical TBI animal models. Adult male Sprague-Dawley rats were exposed to either moderate fluid percussion injury (FPI), controlled cortical impact injury (CCI), or penetrating ballistic-like brain injury (PBBI). Simvastatin (1 or 5 mg/kg) was delivered via oral gavage at 3 h post-injury and continued once daily out to 14 days post-injury. Results indicated an intermediate beneficial effect of simvastatin on motor performance on the gridwalk (FPI), balance beam (CCI), and rotarod tasks (PBBI). No significant therapeutic benefit was detected, however, on cognitive outcome across the OBTT TBI models. In fact, Morris water maze (MWM) performance was actually worsened by treatment in the FPI model and scored full negative points for low dose in the MWM latency and swim distance to locate the hidden platform. A detrimental effect on cortical tissue loss was also seen in the FPI model, and there were no benefits on histology across the other models. Simvastatin also produced negative effects on circulating glial fibrillary acidic protein biomarker outcomes that were evident in the FPI and PBBI models. Overall, the current findings do not support the beneficial effects of simvastatin administration over 2 weeks post-TBI using the oral route of administration and, as such, it will not be further pursued by OBTT.
- Published
- 2016
- Full Text
- View/download PDF
32. Nicotinamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
- Author
-
Shear DA, Dixon CE, Bramlett HM, Mondello S, Dietrich WD, Deng-Bryant Y, Schmid KE, Wang KK, Hayes RL, Povlishock JT, Kochanek PM, and Tortella FC
- Subjects
- Animals, Biomarkers blood, Disease Models, Animal, Dose-Response Relationship, Drug, Glial Fibrillary Acidic Protein blood, Male, Rats, Rats, Sprague-Dawley, Ubiquitin Thiolesterase blood, Brain Injuries, Traumatic, Niacinamide administration & dosage, Recovery of Function drug effects, Vitamin B Complex administration & dosage
- Abstract
Nicotinamide (vitamin B3) was the first drug selected for cross-model testing by the Operation Brain Trauma Therapy (OBTT) consortium based on a compelling record of positive results in pre-clinical models of traumatic brain injury (TBI). Adult male Sprague-Dawley rats were exposed to either moderate fluid percussion injury (FPI), controlled cortical impact injury (CCI), or penetrating ballistic-like brain injury (PBBI). Nicotinamide (50 or 500 mg/kg) was delivered intravenously at 15 min and 24 h after injury with subsequent behavioral, biomarker, and histopathological outcome assessments. There was an intermediate effect on balance beam performance with the high (500 mg/kg) dose in the CCI model, but no significant therapeutic benefit was detected on any other motor task across the OBTT TBI models. There was an intermediate benefit on working memory with the high dose in the FPI model. A negative effect of the low (50 mg/kg) dose, however, was observed on cognitive outcome in the CCI model, and no cognitive improvement was observed in the PBBI model. Lesion volume analysis showed no treatment effects after either FPI or PBBI, but the high dose of nicotinamide resulted in significant tissue sparing in the CCI model. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase-1 (UCH-L1) in blood at 4 or 24 h after injury. Negative effects (both doses) were detected on biomarker levels of GFAP after FPI and on biomarker levels of UCH-L1 after PBBI. The high dose of nicotinamide, however, reduced GFAP levels after both PBBI and CCI. Overall, our results showed a surprising lack of benefit from the low dose nicotinamide. In contrast, and partly in keeping with the literature, some benefit was achieved with the high dose. The marginal benefits achieved with nicotinamide, however, which appeared sporadically across the TBI models, has reduced enthusiasm for further investigation by the OBTT Consortium.
- Published
- 2016
- Full Text
- View/download PDF
33. Insight into Pre-Clinical Models of Traumatic Brain Injury Using Circulating Brain Damage Biomarkers: Operation Brain Trauma Therapy.
- Author
-
Mondello S, Shear DA, Bramlett HM, Dixon CE, Schmid KE, Dietrich WD, Wang KK, Hayes RL, Glushakova O, Catania M, Richieri SP, Povlishock JT, Tortella FC, and Kochanek PM
- Subjects
- Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Male, Rats, Rats, Sprague-Dawley, Biomarkers blood, Brain Injuries, Traumatic blood, Glial Fibrillary Acidic Protein blood, Ubiquitin Thiolesterase blood
- Abstract
Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats--namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24-4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI + VEH groups across experiments, no differences were found in the same model. GFAP was acutely increased in injured rats in each model, with significant differences in levels and temporal patterns mirrored by significant differences in delta 24-4 h GFAP levels and neuropathological and behavioral outcomes. Circulating GFAP levels at 4 and 24 h were powerful predictors of 21 day contusion volume and tissue loss. UCH-L1 showed similar tendencies, albeit with less robust differences between sham and injury groups. Significant differences were also found comparing shams across the models. Our findings (1) demonstrate that TBI models display specific biomarker profiles, functional deficits, and pathological consequence; (2) support the concept that there are different cellular, molecular, and pathophysiological responses to TBI in each model; and (3) advance our understanding of TBI, providing opportunities for a successful translation and holding promise for theranostic applications. Based on our findings, additional studies in pre-clinical models should pursue assessment of GFAP as a surrogate histological and/or theranostic end-point.
- Published
- 2016
- Full Text
- View/download PDF
34. Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
- Author
-
Browning M, Shear DA, Bramlett HM, Dixon CE, Mondello S, Schmid KE, Poloyac SM, Dietrich WD, Hayes RL, Wang KK, Povlishock JT, Tortella FC, and Kochanek PM
- Subjects
- Animals, Biomarkers blood, Disease Models, Animal, Glial Fibrillary Acidic Protein blood, Levetiracetam, Male, Piracetam pharmacology, Rats, Rats, Sprague-Dawley, Ubiquitin Thiolesterase blood, Brain Injuries, Traumatic, Nootropic Agents pharmacology, Piracetam analogs & derivatives, Recovery of Function drug effects
- Abstract
Levetiracetam (LEV) is an antiepileptic agent targeting novel pathways. Coupled with a favorable safety profile and increasing empirical clinical use, it was the fifth drug tested by Operation Brain Trauma Therapy (OBTT). We assessed the efficacy of a single 15 min post-injury intravenous (IV) dose (54 or 170 mg/kg) on behavioral, histopathological, and biomarker outcomes after parasagittal fluid percussion brain injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI) in rats. In FPI, there was no benefit on motor function, but on Morris water maze (MWM), both doses improved latencies and path lengths versus vehicle (p < 0.05). On probe trial, the vehicle group was impaired versus sham, but both LEV treated groups did not differ versus sham, and the 54 mg/kg group was improved versus vehicle (p < 0.05). No histological benefit was seen. In CCI, there was a benefit on beam balance at 170 mg/kg (p < 0.05 vs. vehicle). On MWM, the 54 mg/kg dose was improved and not different from sham. Probe trial did not differ between groups for either dose. There was a reduction in hemispheric tissue loss (p < 0.05 vs. vehicle) with 170 mg/kg. In PBBI, there was no motor, cognitive, or histological benefit from either dose. Regarding biomarkers, in CCI, 24 h glial fibrillary acidic protein (GFAP) blood levels were lower in the 170 mg/kg group versus vehicle (p < 0.05). In PBBI, GFAP blood levels were increased in vehicle and 170 mg/kg groups versus sham (p < 0.05) but not in the 54 mg/kg group. No treatment effects were seen for ubiquitin C-terminal hydrolase-L1 across models. Early single IV LEV produced multiple benefits in CCI and FPI and reduced GFAP levels in PBBI. LEV achieved 10 points at each dose, is the most promising drug tested thus far by OBTT, and the only drug to improve cognitive outcome in any model. LEV has been advanced to testing in the micropig model in OBTT.
- Published
- 2016
- Full Text
- View/download PDF
35. Comprehensive Evaluation of Neuroprotection Achieved by Extended Selective Brain Cooling Therapy in a Rat Model of Penetrating Ballistic-Like Brain Injury.
- Author
-
Lu XC, Shear DA, Deng-Bryant Y, Leung LY, Wei G, Chen Z, and Tortella FC
- Subjects
- Animals, Brain pathology, Brain Injuries, Traumatic pathology, Electroencephalography, Head Injuries, Penetrating pathology, Isoflurane, Male, Maze Learning, Models, Animal, Random Allocation, Rats, Sprague-Dawley, Rotarod Performance Test, Brain Injuries, Traumatic therapy, Head Injuries, Penetrating therapy, Hypothermia, Induced
- Abstract
Brain hypothermia has been considered as a promising alternative to whole-body hypothermia in treating acute neurological disease, for example, traumatic brain injury. Previously, we demonstrated that 2-hours selective brain cooling (SBC) effectively mitigated acute (≤24 hours postinjury) neurophysiological dysfunction induced by a penetrating ballistic-like brain injury (PBBI) in rats. This study evaluated neuroprotective effects of extended SBC (4 or 8 hours in duration) on sub-acute secondary injuries between 3 and 21 days postinjury (DPI). SBC (34°C) was achieved via extraluminal cooling of rats' bilateral common carotid arteries (CCA). Depending on the experimental design, SBC was introduced either immediately or with a 2- or 4-hour delay after PBBI and maintained for 4 or 8 hours. Neuroprotective effects of SBC were evaluated by measuring brain lesion volume, axonal injury, neuroinflammation, motor and cognitive functions, and post-traumatic seizures. Compared to untreated PBBI animals, 4 or 8 hours SBC treatment initiated immediately following PBBI produced comparable neuroprotective benefits against PBBI-induced early histopathology at 3 DPI as evidenced by significant reductions in brain lesion volume, axonal pathology (beta-amyloid precursor protein staining), neuroinflammation (glial fibrillary acetic protein stained-activated astrocytes and rat major histocompatibility complex class I stained activated microglial cell), and post-traumatic nonconvulsive seizures. In the later phase of the injury (7-21 DPI), significant improvement on motor function (rotarod test) was observed under most SBC protocols, including the 2-hour delay in SBC initiation. However, SBC treatment failed to improve cognitive performance (Morris water maze test) measured 13-17 DPI. The protective effects of SBC on delayed axonal injury (silver staining) were evident out to 14 DPI. In conclusion, the CCA cooling method of SBC produced neuroprotection measured across multiple domains that were evident days/weeks beyond the cooling duration and in the absence of overt adverse effects. These "proof-of-concept" results suggest that SBC may provide an attractive neuroprotective approach for clinical considerations.
- Published
- 2016
- Full Text
- View/download PDF
36. Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury.
- Author
-
Welch RD, Ayaz SI, Lewis LM, Unden J, Chen JY, Mika VH, Saville B, Tyndall JA, Nash M, Buki A, Barzo P, Hack D, Tortella FC, Schmid K, Hayes RL, Vossough A, Sweriduk ST, and Bazarian JJ
- Subjects
- Adult, Aged, Biomarkers blood, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Brain Injuries blood, Brain Injuries diagnostic imaging, Glial Fibrillary Acidic Protein blood, S100 Calcium Binding Protein beta Subunit blood, Tomography, X-Ray Computed standards, Ubiquitin Thiolesterase blood
- Abstract
Head computed tomography (CT) imaging is still a commonly obtained diagnostic test for patients with minor head injury despite availability of clinical decision rules to guide imaging use and recommendations to reduce radiation exposure resulting from unnecessary imaging. This prospective multicenter observational study of 251 patients with suspected mild to moderate traumatic brain injury (TBI) evaluated three serum biomarkers' (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1] and S100B measured within 6 h of injury) ability to differentiate CT negative and CT positive findings. Of the 251 patients, 60.2% were male and 225 (89.6%) had a presenting Glasgow Coma Scale score of 15. A positive head CT (intracranial injury) was found in 36 (14.3%). UCH-L1 was 100% sensitive and 39% specific at a cutoff value >40 pg/mL. To retain 100% sensitivity, GFAP was 0% specific (cutoff value 0 pg/mL) and S100B had a specificity of only 2% (cutoff value 30 pg/mL). All three biomarkers had similar values for areas under the receiver operator characteristic curve: 0.79 (95% confidence interval; 0.70-0.88) for GFAP, 0.80 (0.71-0.89) for UCH-L1, and 0.75 (0.65-0.85) for S100B. Neither GFAP nor UCH-L1 curve values differed significantly from S100B (p = 0.21 and p = 0.77, respectively). In our patient cohort, UCH-L1 outperformed GFAP and S100B when the goal was to reduce CT use without sacrificing sensitivity. UCH-L1 values <40 pg/mL could potentially have aided in eliminating 83 of the 215 negative CT scans. These results require replication in other studies before the test is used in actual clinical practice.
- Published
- 2016
- Full Text
- View/download PDF
37. Neuroprotection and anti-seizure effects of levetiracetam in a rat model of penetrating ballistic-like brain injury.
- Author
-
Caudle KL, Lu XC, Mountney A, Shear DA, and Tortella FC
- Subjects
- Analysis of Variance, Animals, Disease Models, Animal, Electroencephalography, Gait Disorders, Neurologic drug therapy, Gait Disorders, Neurologic etiology, Gene Expression Regulation drug effects, Levetiracetam, Male, Maze Learning drug effects, Motor Activity drug effects, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Piracetam pharmacology, Piracetam therapeutic use, Rats, Rats, Sprague-Dawley, Reaction Time drug effects, Statistics, Nonparametric, Time Factors, Trauma Severity Indices, Treatment Outcome, Head Injuries, Penetrating complications, Head Injuries, Penetrating drug therapy, Piracetam analogs & derivatives, Seizures drug therapy, Seizures etiology
- Abstract
Purpose: We assessed the therapeutic efficacy of FDA-approved anti-epileptic drug Levetiracetam (LEV) to reduce post-traumatic nonconvulsive seizure (NCS) activity and promote neurobehavioral recovery following 10% frontal penetrating ballistic-like brain injury (PBBI) in male Sprague-Dawley rats., Methods: Experiment 1 anti-seizure study: 50 mg/kg LEV (25 mg/kg maintenance doses) was given twice daily for 3 days (LEV3D) following PBBI; outcome measures included seizures incidence, frequency, duration, and onset. Experiment 2 neuroprotection studies: 50 mg/kg LEV was given twice daily for either 3 (LEV3D) or 10 days (LEV10D) post-injury; outcome measures include motor (rotarod) and cognitive (water maze) functions., Results: LEV3D treatment attenuated seizure activity with significant reductions in NCS incidence (54%), frequency, duration, and delayed latency to seizure onset compared to vehicle treatment. LEV3D treatment failed to improve cognitive or motor performance; however extending the dosing regimen through 10 days post-injury afforded significant neuroprotective benefit. Animals treated with the extended LEV10D dosing regimen showed a twofold improvement in rotarod task latency to fall as well as significantly improved spatial learning performance (24%) in the MWM task., Conclusions: These findings support the dual anti- seizure and neuroprotective role of LEV, but more importantly identify the importance of an extended dosing protocol which was specific to the therapeutic targets studied.
- Published
- 2016
- Full Text
- View/download PDF
38. Challenging the Paradigms of Experimental TBI Models: From Preclinical to Clinical Practice.
- Author
-
Tortella FC
- Subjects
- Animals, Brain Injuries, Traumatic diagnosis, Brain Injuries, Traumatic therapy, Humans, Translational Research, Biomedical, Brain Injuries, Traumatic etiology, Brain Injuries, Traumatic pathology, Disease Models, Animal
- Abstract
Despite prodigious advances in TBI neurobiology research and a broad arsenal of animal models mimicking different aspects of human brain injury, this field has repeatedly experienced collective failures to translate from animals to humans, particularly in the area of therapeutics. This lack of success stems from variability and inconsistent standardization across models and laboratories, as well as insufficient objective and quantifiable diagnostic measures (biomarkers, high-resolution imaging), understanding of the vast clinical heterogeneity, and clinically centered conception of the TBI animal models. Significant progress has been made by establishing well-defined standards for reporting animal studies with "preclinical common data elements" (CDE), and for the reliability and reproducibility in preclinical TBI therapeutic research with the Operation Brain Trauma Therapy (OBTT) consortium. However, to break the chain of failures and achieve a therapeutic breakthrough in TBI will probably require the use of higher species models, specific mechanism-based injury models by which to theranostically targeted treatment portfolios are tested, more creative concepts of therapy intervention including combination therapy and regeneration neurobiology strategies, and the adoption of dosing regimens based upon pharmacokinetic-pharmacodynamic (PK-PD) studies and guided by the injury severity and TBI recovery process.
- Published
- 2016
- Full Text
- View/download PDF
39. Serum Glial Fibrillary Acidic Protein Predicts Tissue Glial Fibrillary Acidic Protein Break-Down Products and Therapeutic Efficacy after Penetrating Ballistic-Like Brain Injury.
- Author
-
Boutté AM, Deng-Bryant Y, Johnson D, Tortella FC, Dave JR, Shear DA, and Schmid KE
- Subjects
- Animals, Biomarkers blood, Disease Models, Animal, Glial Fibrillary Acidic Protein blood, Head Injuries, Penetrating blood, Male, Rats, Rats, Sprague-Dawley, Ubiquitin Thiolesterase blood, Glial Fibrillary Acidic Protein metabolism, Head Injuries, Penetrating metabolism, Spectrin metabolism, Ubiquitin Thiolesterase metabolism
- Abstract
Acute traumatic brain injury (TBI) is associated with neurological dysfunction, changes in brain proteins, and increased serum biomarkers. However, the relationship between these brain proteins and serum biomarkers, and the ability of these serum biomarkers to indicate a neuroprotective/therapeutic response, remains elusive. Penetrating ballistic-like brain injury (PBBI) was used to systematically analyze several key TBI biomarkers, glial fibrillary acidic protein (GFAP) and its break-down products (BDPs)-ubiquitin C-terminal hydrolase-L1 (UCH-L1), α-II spectrin, and α-II spectrin BDPs (SBDPs)-in brain tissues and serum during an extended acute-subacute time-frame. In addition, neurological improvement and serum GFAP theranostic value was evaluated after neuroprotective treatment. In brain tissues, total GFAP increased more than three-fold 2 to 7 d after PBBI. However, this change was primarily due to GFAP-BDPs which increased to 2.7-4.8 arbitrary units (AU). Alpha-II spectrin was nearly ablated 3 d after PBBI, but somewhat recovered after 7 d. In conjunction with α-II spectrin loss, SBDP-145/150 increased approximately three-fold 2 to 7 d after PBBI (vs. sham, p<0.05). UCH-L1 protein levels were slightly decreased 7 d after PBBI but otherwise were unaffected. Serum GFAP was elevated by 3.2- to 8.8-fold at 2 to 4 h (vs. sham; p<0.05) and the 4 h increase was strongly correlated to 3 d GFAP-BDP abundance (r=0.66; p<0.05). Serum GFAP showed such a strong injury effect that it also was evaluated after therapeutic intervention with cyclosporin A (CsA). Administration of 2.5 mg/kg CsA significantly reduced serum GFAP elevation by 22.4-fold 2 h after PBBI (vs. PBBI+vehicle; p<0.05) and improved neurological function 1 d post-injury. Serum biomarkers, particularly GFAP, may be correlative tools of brain protein changes and feasible theranostic markers of TBI progression and recovery.
- Published
- 2016
- Full Text
- View/download PDF
40. Advanced and High-Throughput Method for Mitochondrial Bioenergetics Evaluation in Neurotrauma.
- Author
-
Pandya JD, Sullivan PG, Leung LY, Tortella FC, Shear DA, and Deng-Bryant Y
- Subjects
- Animals, Cell Respiration drug effects, Drug Discovery, Drug Evaluation, Preclinical, Male, Metabolomics methods, Mitochondria drug effects, Oxidative Phosphorylation, Rats, Reactive Oxygen Species metabolism, Trauma, Nervous System drug therapy, Energy Metabolism, High-Throughput Screening Assays, Mitochondria metabolism, Trauma, Nervous System etiology, Trauma, Nervous System metabolism
- Abstract
Mitochondrial dysfunction is one of the key posttraumatic neuropathological events observed in various experimental models of traumatic brain injury (TBI). The extent of mitochondrial dysfunction has been associated with the severity and time course of secondary injury following brain trauma. Critically, several mitochondrial targeting preclinical drugs used in experimental TBI models have shown improved mitochondrial bioenergetics, together with cortical tissue sparing and cognitive behavioral outcome. Mitochondria, being a central regulator of cellular metabolic pathways and energy producer of cells, are of a great interest for researchers aiming to adopt cutting-edge methodology for mitochondrial bioenergetics assessment. The traditional way of mitochondrial bioenergetics analysis utilizing a Clark-type oxygen electrode (aka. oxytherm) is time-consuming and labor-intensive. In the present chapter, we describe an advanced and high-throughput method for mitochondrial bioenergetics assessments utilizing the Seahorse Biosciences XF(e)24 Flux Analyzer. This allows for simultaneous measurement of multiple samples with higher efficiency than the oxytherm procedure. This chapter provides helpful guidelines for conducting mitochondrial isolation and studying mitochondrial bioenergetics in brain tissue homogenates following experimental TBI.
- Published
- 2016
- Full Text
- View/download PDF
41. Pre-Clinical Traumatic Brain Injury Common Data Elements: Toward a Common Language Across Laboratories.
- Author
-
Smith DH, Hicks RR, Johnson VE, Bergstrom DA, Cummings DM, Noble LJ, Hovda D, Whalen M, Ahlers ST, LaPlaca M, Tortella FC, Duhaime AC, and Dixon CE
- Subjects
- Animals, Blast Injuries pathology, Brain Hemorrhage, Traumatic pathology, Computational Biology, Humans, Laboratories, Meta-Analysis as Topic, Models, Animal, Models, Neurological, Public Health, Reference Standards, Brain Injuries pathology, Common Data Elements, Databases, Factual
- Abstract
Traumatic brain injury (TBI) is a major public health issue exacting a substantial personal and economic burden globally. With the advent of "big data" approaches to understanding complex systems, there is the potential to greatly accelerate knowledge about mechanisms of injury and how to detect and modify them to improve patient outcomes. High quality, well-defined data are critical to the success of bioinformatics platforms, and a data dictionary of "common data elements" (CDEs), as well as "unique data elements" has been created for clinical TBI research. There is no data dictionary, however, for preclinical TBI research despite similar opportunities to accelerate knowledge. To address this gap, a committee of experts was tasked with creating a defined set of data elements to further collaboration across laboratories and enable the merging of data for meta-analysis. The CDEs were subdivided into a Core module for data elements relevant to most, if not all, studies, and Injury-Model-Specific modules for non-generalizable data elements. The purpose of this article is to provide both an overview of TBI models and the CDEs pertinent to these models to facilitate a common language for preclinical TBI research.
- Published
- 2015
- Full Text
- View/download PDF
42. Dual Therapeutic Effects of C-10068, a Dextromethorphan Derivative, Against Post-Traumatic Nonconvulsive Seizures and Neuroinflammation in a Rat Model of Penetrating Ballistic-Like Brain Injury.
- Author
-
Lu XC, Shear DA, Graham PB, Bridson GW, Uttamsingh V, Chen Z, Leung LY, and Tortella FC
- Subjects
- Animals, Astrocytes drug effects, Behavior, Animal drug effects, Disease Models, Animal, Electroencephalography, Head Injuries, Penetrating complications, Head Injuries, Penetrating immunology, Hippocampus drug effects, Inflammation etiology, Male, Microglia drug effects, Rats, Rats, Sprague-Dawley, Seizures etiology, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents pharmacology, Anticonvulsants administration & dosage, Anticonvulsants pharmacology, Dextromethorphan administration & dosage, Dextromethorphan analogs & derivatives, Dextromethorphan pharmacology, Excitatory Amino Acid Antagonists administration & dosage, Excitatory Amino Acid Antagonists pharmacology, Head Injuries, Penetrating drug therapy, Inflammation drug therapy, Seizures drug therapy
- Abstract
Post-traumatic seizures can exacerbate injurious outcomes of severe brain trauma, yet effective treatments are limited owing to the complexity of the pathology underlying the concomitant occurrence of both events. In this study, we tested C-10068, a novel deuterium-containing analog of (+)-N-methyl-3-ethoxymorphinan, in a rat model of penetrating ballistic-like brain injury (PBBI) and evaluated the effects of C-10068 on PBBI-induced nonconvulsive seizures (NCS), acute neuroinflammation, and neurofunctional outcomes. NCS were detected by electroencephalographic monitoring. Neuroinflammation was evaluated by immunohistochemical markers, for example, glial fibrillary acidic protein and major histocompatibility complex class I, for activation of astrocytes and microglia, respectively. Neurofunction was tested using rotarod and Morris water maze tasks. Three infusion doses of C-10068 (1.0, 2.5, and 5.0 mg/kg/h × 72 h) were tested in the antiseizure study. Neuroinflammation and neurofunction were evaluated in animals treated with 5.0 mg/kg/h × 72 h C-10068. Compared to vehicle treatment, C-10068 dose dependently reduced PBBI-induced NCS incidence (40-50%), frequency (20-70%), and duration (30-82%). The most effective antiseizure dose of C-10068 (5.0 mg/kg/h × 72 h) also significantly attenuated hippocampal astrocyte activation and perilesional microglial reactivity post-PBBI. Within C-10068-treated animals, a positive correlation was observed in reduction in NCS frequency and reduction in hippocampal astrocyte activation. Further, C-10068 treatment significantly attenuated astrocyte activation in seizure-free animals. However, C-10068 failed to improve PBBI-induced motor and cognitive functions with the dosing regimen used in this study. Overall, the results indicating that C-10068 exerts both potent antiseizure and antiinflammatory effects are promising and warrant further investigation.
- Published
- 2015
- Full Text
- View/download PDF
43. Decline in arylsulfatase B and Increase in chondroitin 4-sulfotransferase combine to increase chondroitin 4-sulfate in traumatic brain injury.
- Author
-
Bhattacharyya S, Zhang X, Feferman L, Johnson D, Tortella FC, Guizzetti M, and Tobacman JK
- Subjects
- Animals, Brain Injuries pathology, Cells, Cultured, Female, Male, Pregnancy, Rats, Rats, Sprague-Dawley, Brain Injuries metabolism, Chondroitin Sulfates biosynthesis, N-Acetylgalactosamine-4-Sulfatase metabolism, Sulfotransferases biosynthesis
- Abstract
In an established rat model of penetrating ballistic-like brain injury (PBBI), arylsulfatase B (ARSB; N-acetylgalactosamine 4-sulfatase) activity was significantly reduced at the ipsilateral site of injury, but unaffected at the contralateral site or in sham controls. In addition, the ARSB substrate chondroitin 4-sulfate (C4S) and total sulfated glycosaminoglycans increased. The mRNA expression of chondroitin 4-sulfotransferase 1 (C4ST1; CHST11) and the sulfotransferase activity rose at the ipsilateral site of injury (PBBI-I), indicating contributions from both increased production and reduced degradation to the accumulation of C4S. In cultured, fetal rat astrocytes, following scratch injury, the ARSB activity declined and the nuclear hypoxia inducible factor-1α increased significantly. In contrast, sulfotransferase activity and chondroitin 4-sulfotransferase expression increased following astrocyte exposure to TGF-β1, but not following scratch. These different pathways by which C4S increased in the cell preparations were both evident in the response to injury in the PBBI-I model. Hence, findings support effects of injury because of mechanical disruption inhibiting ARSB and to chemical mediation by TGF-β1 increasing CHST11 expression and sulfotransferase activity. The increase in C4S following traumatic brain injury is because of contributions from impaired degradation and enhanced synthesis of C4S which combine in the pathogenesis of the glial scar. This is the first report of how two mechanisms contribute to the increase in chondroitin 4-sulfate (C4S) in TBI. Following penetrating ballistic-like brain injury in a rat model and in the scratch model of injury in fetal rat astrocytes, Arylsulfatase B activity declined, leading to accumulation of C4S. TGF-β1 exposure increased expression of chondroitin 4-sulfotransferase. Hence, the increase in C4S in TBI is attributable to both impaired degradation and enhanced synthesis, combining in the pathogenesis of the glial scar., (© 2015 International Society for Neurochemistry.)
- Published
- 2015
- Full Text
- View/download PDF
44. Traumatic Brain Injury and Polytrauma in Theaters of Combat: The Case for Neurotrauma Resuscitation?
- Author
-
Tortella FC and Leung LY
- Subjects
- Animals, Blood Coagulation, Brain Edema pathology, Disease Models, Animal, Humans, Inflammation, Military Medicine methods, Military Medicine trends, Oxygen chemistry, Warfare, Brain Injuries therapy, Multiple Trauma therapy, Resuscitation methods
- Abstract
Polytrauma associated with traumatic brain injury (TBI) is defined as a concurrent injury to the brain and one or more body areas or organ systems that results in physical, cognitive, and psychosocial impairments. Consequently, polytrauma accompanied by TBI presents a unique challenge for emergency medicine, in particular, to those associated with the austere environments encountered in military theaters of operation and the logistics of en-route care. Here, we attempt to put needed focus on this medical emergency, specifically addressing the problem of an exsanguinating polytrauma requiring fluid resuscitation complicated by TBI. Critical questions to consider are the following: (1) What is the optimal resuscitation fluid for these patients? (2) In defining the resuscitation fluid, what considerations must be given with regard to the very specific logistics of military operations? and (3) Can treatment of the brain injury be initiated in parallel with resuscitation practices. Recognizing the immense clinical and experimental complexity of this problem, our goal was to encourage research that embraces with high-fidelity 'combined' animal models of polytrauma and TBI with an objective toward elucidating safe and effective neurotherapeutic resuscitation protocols.
- Published
- 2015
- Full Text
- View/download PDF
45. Minor and repetitive head injury.
- Author
-
Buki A, Kovacs N, Czeiter E, Schmid K, Berger RP, Kobeissy F, Italiano D, Hayes RL, Tortella FC, Mezosi E, Schwarcz A, Toth A, Nemes O, and Mondello S
- Subjects
- Brain pathology, Brain Injuries prevention & control, Brain Injuries therapy, Craniocerebral Trauma prevention & control, Craniocerebral Trauma therapy, Humans, Magnetic Resonance Imaging, Risk Factors, Brain surgery, Brain Injuries diagnosis, Craniocerebral Trauma diagnosis, Diagnostic Imaging
- Abstract
Traumatic brain injury (TBI) is the leading cause of death and disability in the young, active population and expected to be the third leading cause of death in the whole world until 2020. The disease is frequently referred to as the silent epidemic, and many authors highlight the "unmet medical need" associated with TBI.The term traumatically evoked brain injury covers a heterogeneous group ranging from mild/minor/minimal to severe/non-salvageable damages. Severe TBI has long been recognized to be a major socioeconomical health-care issue as saving young lives and sometimes entirely restituting health with a timely intervention can indeed be extremely cost efficient.Recently it has been recognized that mild or minor TBI should be considered similarly important because of the magnitude of the patient population affected. Other reasons behind this recognition are the association of mild head injury with transient cognitive disturbances as well as long-term sequelae primarily linked to repeat (sport-related) injuries.The incidence of TBI in developed countries can be as high as 2-300/100,000 inhabitants; however, if we consider the injury pyramid, it turns out that severe and moderate TBI represents only 25-30 % of all cases, while the overwhelming majority of TBI cases consists of mild head injury. On top of that, or at the base of the pyramid, are the cases that never show up at the ER - the unreported injuries.Special attention is turned to mild TBI as in recent military conflicts it is recognized as "signature injury."This chapter aims to summarize the most important features of mild and repetitive traumatic brain injury providing definitions, stratifications, and triage options while also focusing on contemporary knowledge gathered by imaging and biomarker research.Mild traumatic brain injury is an enigmatic lesion; the classification, significance, and its consequences are all far less defined and explored than in more severe forms of brain injury.Understanding the pathobiology and pathomechanisms may aid a more targeted approach in triage as well as selection of cases with possible late complications while also identifying the target patient population where preventive measures and therapeutic tools should be applied in an attempt to avoid secondary brain injury and late complications.
- Published
- 2015
- Full Text
- View/download PDF
46. Treatment with amnion-derived cellular cytokine solution (ACCS) induces persistent motor improvement and ameliorates neuroinflammation in a rat model of penetrating ballistic-like brain injury.
- Author
-
Deng-Bryant Y, Readnower RD, Leung LY, Cunningham TL, Shear DA, and Tortella FC
- Subjects
- Amnion, Animals, Brain drug effects, Brain pathology, Brain physiopathology, Calcium-Binding Proteins metabolism, Disease Models, Animal, Head Injuries, Penetrating pathology, Head Injuries, Penetrating physiopathology, Immunohistochemistry, Male, Maze Learning drug effects, Maze Learning physiology, Microfilament Proteins metabolism, Motor Activity physiology, Neuroimmunomodulation physiology, Peroxidase metabolism, Random Allocation, Rats, Sprague-Dawley, Rotarod Performance Test, Solutions, Cytokines administration & dosage, Head Injuries, Penetrating drug therapy, Motor Activity drug effects, Neuroimmunomodulation drug effects, Neuroprotective Agents administration & dosage
- Abstract
Purpose: The present work compared the behavioral outcomes of ACCS therapy delivered either intravenously (i.v.) or intracerebroventricularly (i.c.v.) after penetrating ballistic-like brain injury (PBBI). Histological markers for neuroinflammation and neurodegeneration were employed to investigate the potential therapeutic mechanism of ACCS., Methods: Experiment-1, ACCS was administered either i.v. or i.c.v. for 1 week post-PBBI. Outcome metrics included behavioral (rotarod and Morris water maze) and gross morphological assessments. Experiment-2, rats received ACCS i.c.v for either 1 or 2 weeks post-PBBI. The inflammatory response was determined by immunohistochemistry for neutrophils and microglia reactivity. Neurodegeneration was visualized using silver staining., Results: Both i.v. and i.c.v. delivery of ACCS improved motor outcome but failed to improve cognitive outcome or tissue sparing. Importantly, only i.c.v. ACCS treatment produced persistent motor improvements at a later endpoint. The i.c.v. ACCS treatment significantly reduced PBBI-induced increase in myeloperoxidase (MPO) and ionized calcium binding adaptor molecule 1 (Iba1) expression. Concomitant reduction of both Iba1 and silver staining were detected in corpus callosum with i.c.v. ACCS treatment., Conclusions: ACCS, as a treatment for TBI, showed promise with regard to functional (motor) recovery and demonstrated strong capability to modulate neuroinflammatory responses that may underline functional recovery. However, the majority of beneficial effects appear restricted to the i.c.v. route of ACCS delivery, which warrants future studies examining delivery routes (e.g. intranasal delivery) which are more clinically viable for the treatment of TBI.
- Published
- 2015
- Full Text
- View/download PDF
47. Brain Injury Markers: Where are We?
- Author
-
Mondello S and Tortella FC
- Published
- 2014
- Full Text
- View/download PDF
48. The challenge of mild traumatic brain injury: role of biochemical markers in diagnosis of brain damage.
- Author
-
Mondello S, Schmid K, Berger RP, Kobeissy F, Italiano D, Jeromin A, Hayes RL, Tortella FC, and Buki A
- Subjects
- Athletic Injuries blood, Athletic Injuries diagnosis, Biomarkers blood, Brain Concussion blood, Brain Concussion diagnosis, Brain Injuries blood, Decision Making, Humans, Biomarkers metabolism, Brain Injuries diagnosis, Brain Injuries metabolism
- Abstract
During the past decade there has been an increasing recognition of the incidence of mild traumatic brain injury (mTBI) and a better understanding of the subtle neurological and cognitive deficits that may result from it. A substantial, albeit suboptimal, effort has been made to define diagnostic criteria for mTBI and improve diagnostic accuracy. Thus, biomarkers that can accurately and objectively detect brain injury after mTBI and, ideally, aid in clinical management are needed. In this review, we discuss the current research on serum biomarkers for mTBI including their rationale and diagnostic performances. Sensitive and specific biomarkers reflecting brain injury can provide important information regarding TBI pathophysiology and serve as candidate markers for predicting abnormal computed tomography findings and/or the development of residual deficits in patients who sustain an mTBI. We also outline the roles of biomarkers in settings of specific interest including pediatric TBI, sports concussions and military injuries, and provide perspectives on the validation of such markers for use in the clinic. Finally, emerging proteomics-based strategies for identifying novel markers will be discussed., (© 2013 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
49. Temporal alterations in aquaporin and transcription factor HIF1α expression following penetrating ballistic-like brain injury (PBBI).
- Author
-
Cartagena CM, Phillips KL, Tortella FC, Dave JR, and Schmid KE
- Subjects
- Animals, Aquaporin 4 genetics, Aquaporins genetics, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Male, Protein Isoforms genetics, Protein Isoforms metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Aquaporin 4 metabolism, Aquaporins metabolism, Brain Injuries metabolism, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Wounds, Gunshot metabolism
- Abstract
Objectives: Brain edema is a primary factor in the morbidity and mortality of traumatic brain injury (TBI). The various isoforms of aquaporin 4 (AQP4) and aquaporin 9 (AQP9) are important factors influencing edema following TBI. Others have reported that these AQPs are regulated by the transcription factor hypoxia inducible factor (HIF) 1α. Therefore, we examined the temporal alterations in the multiple isoforms of AQP4 and AQP9, and its possible upstream regulation by HIF1α, and evaluated whether different severities of penetrating injury influence these mechanisms., Methods: In the penetrating ballistic-like brain injury (PBBI) model, a temporary cavity and resultant injury was formed by the rapid inflation/deflation (i.e. <40ms) of an elastic balloon attached to the end of the custom probe, injuring 10% of total rat brain volume. Tissue from the ipsilateral core and perilesional injury zones was collected. Total RNA was isolated at 4, 12, and 24h, 3 and 7days post-injury (sham and PBBI, n=6 per group). cDNA was synthesized using oligodT primers. Quantitative real time PCR was performed using Taqman expression assays for aqp4 (recognizing all isoforms), aqp9, and hif1α. Using separate animals, tissue lysate was collected at 4 and 24h, 3 and 7days post-injury and analyzed by immunoblot for protein expression of multiple isoforms of AQP4, the single known isoform of AQP9 and for expression of transcription factor HIF1α (sham, probe only control, and PBBI, n=8-10 per group)., Results: Global aqp4 mRNA was decreased at 24h (p<0.01) with PBBI. Three of the four known protein isoforms of AQP4 were detected, M1 (34kDa), M23 (32kDa) and isoform 3 (30kDa). AQP4 M1 decreased at 3 and 7days post-injury (p<0.001; p<0.01). AQP4 M23 levels were highly variable with no significant changes. AQP4 isoform 3 levels were decreased 3days post-PBBI (p<0.05). From 4, 12, and 24h aqp9 mRNA levels were decreased with injury (p<0.01, p<0.05, p<0.01) while AQP9 levels were decreased at 3 and 7days after PBBI (p<0.001, p<0.01). At 12 and 24h post-PBBI hif1α mRNA levels increased (p<0.05, p<0.01) but at 3 and 7days mRNA levels decreased (p<0.05, p<0.01). From 24h and 3 and 7days HIF1α protein levels were decreased (p<0.0001, p<0.0001, p<0.0001). In comparison to probe control, PBBI led to greater decreases in protein for AQP4 M1 (trend), AQP4 isoform 3 (trend), AQP9 (p<0.05) and HIF1α (p<0.05)., Conclusion: PBBI is characterized by a loss of AQP4 M1, AQP4 isoform 3 and AQP9 at delayed time-points. The severity of the injury (PBBI versus probe control) increased these effects. Therefore, AQP9 and the AQP4 M1 isoform may be regulated by HIF1α, but not AQP4 isoform 3. This delayed loss of aquaporins may markedly reduce the ability of the brain to efflux water, contributing to the protracted edema that is a characteristic following severe penetrating TBI. Factors contributing to edema differ with different types and severities of TBI. For example, cellular based edema is more prominent in diffuse non-penetrating TBI whereas vasogenic edema is more prevalent with TBI involving hemorrhage. Molecular regulation leading to edema will likely also differ, such that treatments which have been suggested for non-hemorrhagic moderate TBI, such as the suppression of aquaporins, may be detrimental in more severe forms of TBI., (Published by Elsevier Inc.)
- Published
- 2014
- Full Text
- View/download PDF
50. Correlations between blood-brain barrier disruption and neuroinflammation in an experimental model of penetrating ballistic-like brain injury.
- Author
-
Cunningham TL, Cartagena CM, Lu XC, Konopko M, Dave JR, Tortella FC, and Shear DA
- Subjects
- Animals, Blood-Brain Barrier pathology, Blood-Brain Barrier physiopathology, Brain Edema pathology, Brain Injuries pathology, Head Injuries, Penetrating pathology, Inflammation pathology, Male, Models, Animal, Rats, Rats, Sprague-Dawley, Blood-Brain Barrier injuries, Brain Edema physiopathology, Brain Injuries physiopathology, Head Injuries, Penetrating physiopathology, Inflammation physiopathology
- Abstract
Abstract Blood-brain barrier (BBB) disruption is a pathological hallmark of severe traumatic brain injury (TBI) and is associated with neuroinflammatory events contributing to brain edema and cell death. The goal of this study was to elucidate the profile of BBB disruption after penetrating ballistic-like brain injury (PBBI) in conjunction with changes in neuroinflammatory markers. Brain uptake of biotin-dextran amine (BDA; 3 kDa) and horseradish peroxidase (HRP; 44 kDa) was evaluated in rats at 4 h, 24 h, 48 h, 72 h, and 7 days post-PBBI and compared with the histopathologic and molecular profiles for inflammatory markers. BDA and HRP both displayed a uniphasic profile of extravasation, greatest at 24 h post-injury and which remained evident out to 48 h for HRP and 7 days for BDA. This profile was most closely associated with markers for adhesion (mRNA for intercellular adhesion molecule-1) and infiltration of peripheral granulocytes (mRNA for matrix metalloproteinase-9 [MMP-9] and myeloperoxidase staining). Improvement of BBB dysfunction coincided with increased expression of markers implicated in tissue remodeling and repair. The results of this study reveal a uniphasic and gradient opening of the BBB after PBBI and suggest MMP-9 and resident inflammatory cell activation as candidates for future neurotherapeutic intervention after PBBI.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.